Hims & Hers Health (NYSE:HIMS) Price Target Increased to $16.00 by Analysts at Deutsche Bank Aktiengesellschaft

Hims & Hers Health (NYSE:HIMS) had its target price upped by Deutsche Bank Aktiengesellschaft from $14.00 to $16.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a hold rating on the stock.

A number of other equities research analysts have also recently weighed in on HIMS. Imperial Capital upgraded Hims & Hers Health from an in-line rating to an outperform rating and set a $16.00 price objective for the company in a research note on Wednesday, February 28th. TheStreet upgraded shares of Hims & Hers Health from a d rating to a c rating in a report on Monday, March 4th. Citigroup boosted their price objective on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. Leerink Partnrs restated a market perform rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Finally, Guggenheim upped their price target on Hims & Hers Health from $15.00 to $17.00 and gave the stock a buy rating in a research report on Tuesday, February 27th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $15.07.

Hims & Hers Health Stock Up 6.1 %

Shares of NYSE HIMS opened at $12.36 on Tuesday. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $17.16. The business has a fifty day simple moving average of $14.04 and a two-hundred day simple moving average of $10.35. The firm has a market cap of $2.65 billion, a PE ratio of -112.36 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) earnings per share. On average, research analysts expect that Hims & Hers Health will post 0.11 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,503 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the completion of the transaction, the insider now owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Hims & Hers Health news, CEO Andrew Dudum sold 97,208 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total value of $931,252.64. Following the sale, the chief executive officer now owns 51,653 shares in the company, valued at approximately $494,835.74. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the transaction, the insider now directly owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 736,191 shares of company stock worth $9,733,700. Company insiders own 31.63% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new position in Hims & Hers Health in the 4th quarter worth about $48,000. Cornerstone Investment Partners LLC purchased a new position in shares of Hims & Hers Health during the 1st quarter valued at approximately $161,000. EMC Capital Management grew its stake in Hims & Hers Health by 80.0% in the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after acquiring an additional 5,332 shares during the period. Belpointe Asset Management LLC purchased a new stake in Hims & Hers Health in the 3rd quarter worth $76,000. Finally, Certuity LLC acquired a new position in Hims & Hers Health during the fourth quarter worth $109,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.